Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
YOLT-204 for Transfusion-Dependent Beta-Thalassemia
NCT06678165Phase 1Not yet recruiting
- Sponsor
- The First Affiliated Hospital of Guangxi Medical University
- Start
- Dec 2024
- Primary completion
- Jun 2026
- Modality
- Gene Editing, Gene Silencing, Lipid-based Nanoparticles
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of YOLT-204 in beta thalassemia, sponsored by The First Affiliated Hospital of Guangxi Medical University. Primary endpoints: Treatment-Emergent Adverse Events at 52 weeks, Laboratory Test Findings at 52 weeks and 3 more. Planned start Dec 2024; status: not yet recruiting.
02
Drugs
YOLT-204
03
Conditions
beta thalassemia
Beyond the preview
Go deeper on NCT06678165.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06678165.